Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 50 3-Year EBITDA Growth Rate is 20.90% as of Dec. 2025, which is at its 10-year median of 20.90. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Inspecs Group ranks better than 66.81% on this metric.
During the past 12 months, Inspecs Group's average EBITDA Per Share Growth Rate was -16.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Inspecs Group was 1026.50% per year. The lowest was -85.10% per year. And the median was 20.90% per year.
Inspecs Group (LSE:SPEC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Inspecs Group 3-Year EBITDA Growth Rate Related Terms
LSE:SPEC vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Inspecs Group's 3-Year EBITDA Growth Rate falls into.
Inspecs Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.90% mean?
Inspecs Group (LSE:SPEC) has a 3-Year EBITDA Growth Rate of 20.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Inspecs Group and its competitors. This is near median its historical median of 20.90. According to the industry distribution chart, Inspecs Group ranks #230 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Inspecs Group's 3-Year EBITDA Growth Rate too high?
Inspecs Group's current 3-Year EBITDA Growth Rate of 20.90% is near median its 10-year median of 20.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.30. Inspecs Group's value of 20.90% is 151.8% above this industry median. Based on the distribution chart, Inspecs Group ranks #230 out of 693 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #230 out of 693 companies for 3-Year EBITDA Growth Rate. This puts Inspecs Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.30. Inspecs Group's value of 20.90% is 151.8% above this benchmark. While the company's 10-year median is 20.90 vs. the industry median of 8.30, Inspecs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.30, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current 3-Year EBITDA Growth Rate of 20.90% is 151.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current 3-Year EBITDA Growth Rate is 20.90%, which is near median its own 10-year median of 20.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.97 — trading 67.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.90%, which is near median its 10-year median of 20.90 and 151.8% above the Medical Devices & Instruments industry median of 8.30. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current 3-Year EBITDA Growth Rate is 20.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.97 is trading 67.2% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
3-Year EBITDA Growth Rate: 20.90% (near median its 10-year median of 20.90)
GF Value™: £0.58 vs. price of £0.97 (67.2% above fair value)
Industry Position: 151.8% above the Medical Devices & Instruments median (#230 of 693)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
